Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Human Papillomavirus

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    138 result(s) found for: Human Papillomavirus. Displaying page 6 of 7.
    « Previous 1  2  3  4  5  6  7  Next»
    EudraCT Number: 2008-006208-52 Sponsor Protocol Number: IFN005 Start Date*: 2009-03-09
    Sponsor Name:Helix BioPharma Cooperation
    Full Title: Mono-centre, open-label study to investigate the multi-dose pharmacokinetics, efficacy and safety of Interferon alpha-2b Cream in women with a history of cytological diagnosed Pap IIID, with a con...
    Medical condition: cervical dysplasia (CIN I or CIN II; Pap IIID in the history, confirmed HPV+ status)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10008263 Cervical dysplasia LLT
    Population Age: Adults Gender: Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-005466-34 Sponsor Protocol Number: HPVAIN1 Start Date*: Information not available in EudraCT
    Sponsor Name:Academic Medical Center
    Full Title: Therapeutic Vaccination against Human Papillomavirus Type 16 for the Treatment of Anal Intraepithelial Neoplasia in HIV+ Men
    Medical condition: HPV16-induced intra-anal high-grade AIN (grade 2-3) in HIV+ men, that was resistant to, or recurred after conventional cauterization or other forms of local treatment.
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004856 10059312 Anal dysplasia LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2023-000183-65 Sponsor Protocol Number: TTCC-2022-01-RADIAN Start Date*: 2023-08-23
    Sponsor Name:Grupo Español de Tratamiento de Tumores de Cabeza y Cuello (TTCC)
    Full Title: Phase Ib/II non-randomized non-comparative two-cohort study of Niraparib and Dostarlimab plus (Chemo)RadIotherapy in Locally-Advanced head and Neck squamous cell carcinoma (RADIAN)
    Medical condition: Locally-Advanced head and Neck squamous cell carcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060121 Squamous cell carcinoma of head and neck PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-000881-39 Sponsor Protocol Number: P/2019/418 Start Date*: 2019-12-10
    Sponsor Name:CHU de Besançon
    Full Title: A phase II study evaluating the interest to combine UCPVax a CD4 TH1-inducer cancer vaccine and atezolizumab for the treatment of HPV positive cancers
    Medical condition: cancers induits par HPV (Human PapillomaVirus) (cancers ORL, du col de l'utérus, de la vulve et du canal anal
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-006738-33 Sponsor Protocol Number: CL-1205 Start Date*: 2008-03-14
    Sponsor Name:NatImmune A/S
    Full Title: bLAC - A phase II double-blind, placebo controlled, clinical proof of concept trial of the efficacy of 8 weeks treatment of cutaneous warts with bLAC in immune suppressed, kidney transplanted patients
    Medical condition: Cutaneous wart lesions on hands and/or feet at immune suppressed, kidney transplanted patients.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010115 Common warts LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-001239-29 Sponsor Protocol Number: R2810-ONC-ISA-1981 Start Date*: 2021-07-22
    Sponsor Name:Regeneron Pharmaceuticals, Inc.
    Full Title: A Phase 2 Study of Cemiplimab, an Anti-PD-1 Monoclonal Antibody, and ISA101b Vaccine in Patients with Recurrent/Metastatic HPV16 Cervical Cancer who have Experienced Disease Progression after First...
    Medical condition: Recurrent/Metastatic HPV16 Cervical Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10008229 Cervical cancer LLT
    21.1 100000004864 10008231 Cervical cancer recurrent LLT
    20.1 100000004862 10063001 Human papilloma virus infection LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Completed) BE (Completed) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2009-012210-48 Sponsor Protocol Number: 20407 Start Date*: 2009-08-06
    Sponsor Name:Leiden University Medical Centre
    Full Title: Monochloroacetic acid versus cryotherapy in the treatment of warts: A Randomised Clinical Trial (WARTS-2)
    Medical condition: All patients from the age of 4 onward, who present themselves to their practice with one or more new warts of the type vulgaris on hands or feet.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010115 Common warts LLT
    9.1 10035158 Plantar warts LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-016302-16 Sponsor Protocol Number: DPSI-IDP-109-P2-01 Start Date*: 2010-03-19
    Sponsor Name:Dow Pharmaceutical Sciences Inc.
    Full Title: A Randomized, Double-Blind, Vehicle-Controlled Study Evaluating the Safety and Efficacy of IDP-109 Solution in the Treatment of Patients with Verrucae Vulgares
    Medical condition: Verrucae vulgares
    Disease: Version SOC Term Classification Code Term Level
    12.1 10010115 Common warts LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-000907-34 Sponsor Protocol Number: H-200-001 Start Date*: 2021-11-11
    Sponsor Name:Hookipa Biotech GmbH
    Full Title: A Phase I/II Study of TheraT® Vector(s) Expressing Human Papillomavirus 16 Positive (HPV 16+) Specific Antigens in Patients with HPV 16+ Confirmed Cancers
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10081287 HPV positive oropharyngeal squamous cell carcinoma LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041823 Squamous cell carcinoma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10063569 Metastatic squamous cell carcinoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10046885 Vaginal cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008229 Cervical cancer LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061424 Anal cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10034299 Penile cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10047777 Vulvar cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) FR (Ongoing) NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-002852-19 Sponsor Protocol Number: BO42533 Start Date*: 2021-03-10
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE II, RANDOMIZED, DOUBLE-BLIND STUDY OF ATEZOLIZUMAB PLUS TIRAGOLUMAB AND ATEZOLIZUMAB PLUS PLACEBO AS FIRST-LINE TREATMENT IN PATIENTS WITH RECURRENT/METASTATIC PD-L1 POSITIVE SQUAMOUS CELL ...
    Medical condition: Squamous cell carcinoma of the head and neck (SCCHN).
    Disease: Version SOC Term Classification Code Term Level
    22.0 100000004864 10082179 Squamous cell carcinoma of head and neck metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) PL (Trial now transitioned) HU (Trial now transitioned) CZ (Trial now transitioned) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-004347-30 Sponsor Protocol Number: 110886 Start Date*: 2007-11-07
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase IIIb, randomized, open, multicentre study to evaluate the immunogenicity and safety of GlaxoSmithKline Biologicals’ HPV-16/18 L1 VLP AS04 vaccine co-administered with GlaxoSmithKline Biolog...
    Medical condition: For active immunization of females from the age of 10 years onwards for the prevention of cervical cancer by protecting against incident and persistent infections, cytological abnormalities includi...
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Female
    Trial protocol: SE (Completed) HU (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2017-003702-41 Sponsor Protocol Number: IDR-OM-02 Start Date*: 2018-07-03
    Sponsor Name:Soligenix UK Limited
    Full Title: A Pivotal, Double-Blind, Randomized, Placebo-Controlled, Multinational Study of SGX942 (Dusquetide) for the Treatment of Oral Mucositis in Patients Being Treated With Concomitant Chemoradiation for...
    Medical condition: Oral Mucositis in Patients Being Treated with Concomitant Chemoradiation for the Treatment of Squamous Cell Carcinoma of the Head and Neck
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) FR (Ongoing) ES (Completed) HU (Completed) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-001731-55 Sponsor Protocol Number: 106636 Start Date*: 2007-08-09
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase III/IV, community-randomized, controlled study to evaluate the effectiveness of two vaccination strategies using GlaxoSmithKline Biologicals’ HPV-16/18 L1 VLP AS04 vaccine in reducing the p...
    Medical condition: For the prevention of high-grade cervical intraepithelial neoplasia (CIN grades 2 and 3) and cervical cancer causally related to human papillomavirus (HPV) types 16 and 18.
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10008230 Cervix neoplasms malignant HLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2007-003256-11 Sponsor Protocol Number: 109179 (HPV-044 PRI) Start Date*: 2007-10-02
    Sponsor Name:GLAXO SMITHKLINE
    Full Title: A phase IIIb open, randomized multi-center study to evaluate the immunogenicity and safety of GSK Biologicals HPV-16/18 L1 VLP AS04 vaccine when administered intramuscularly according to an alterna...
    Medical condition: For active immunization of females from the age of 10 years onwards to prevent incident and persistent infections, cytological abnormalities and cervical neoplasia (CIN), CIN 1 and pre-cancerous...
    Disease: Version SOC Term Classification Code Term Level
    6.1 10029109 HLT
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: IT (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2017-003302-40 Sponsor Protocol Number: WO40242 Start Date*: 2018-04-10
    Sponsor Name:F. Hoffman-La Roche Ltd.
    Full Title: A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) AS ADJUVANT THERAPY AFTER DEFINITIVE LOCAL THERAPY IN PATIENTS WITH HIGH-RISK LOCA...
    Medical condition: Locally advanced squamous cell carcinoma of the head and neck (SCCHN)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041823 Squamous cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Ongoing) GB (GB - no longer in EU/EEA) PL (Completed) FR (Completed) BE (Completed) PT (Completed) HU (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-003688-39 Sponsor Protocol Number: CLS003-CO-PR-002 Start Date*: 2014-11-26
    Sponsor Name:Cutanea Life Sciences
    Full Title: A Phase 2, Randomized, Vehicle-Controlled, Double-Blind, Proof-of-Concept Study to Evaluate Efficacy and Safety of Topical Ionic Contra-viral Therapy (ICVT) Comprised of Digoxin and Furosemide in C...
    Medical condition: Patients with at least two warts who are otherwise healthy subjects
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004864 10010115 Common warts LLT
    17.1 100000004864 10035158 Plantar warts LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-008169-36 Sponsor Protocol Number: UMCUHPV Start Date*: 2009-02-17
    Sponsor Name:University Medical Center Utrecht
    Full Title: Immune response after Human Papillomavirus vaccination in patients with auto-immune disease
    Medical condition: Juvenile Idiopathic Arthritis Systemic lupus erythematosus childhood dermatomyositis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10042947 Systemic lupus erythematosus synd LLT
    9.1 10059176 Juvenile idiopathic arthritis LLT
    9.1 10008521 Childhood dermatomyositis LLT
    Population Age: Adolescents, Under 18 Gender: Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-003690-10 Sponsor Protocol Number: 2125-MST-206 Start Date*: 2019-06-21
    Sponsor Name:Idera Pharmaceuticals, Inc.
    Full Title: Study of Tilsotolimod in Combination with Nivolumab and Ipilimumab for the Treatment of Solid Tumors
    Medical condition: Cohort 1: IO Naive Relapsed/Metastatic Squamous Cell Carcinoma of the Head and Neck
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060121 Squamous cell carcinoma of head and neck PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-004893-42 Sponsor Protocol Number: 1.0 Start Date*: 2008-10-15
    Sponsor Name:Medizinische Universität Wien, Universitätsklinik für dermatologie
    Full Title:
    Medical condition: Condyloma accuminata, Vulvar Intraepithelial Neoplasia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10047762 Vulval neoplasms benign HLT
    9.1 10010291 Condyloma acuminatum LLT
    Population Age: Adults Gender: Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2019-004697-25 Sponsor Protocol Number: V528Nov22 Start Date*: 2020-09-14
    Sponsor Name:The Rotunda Hospital
    Full Title: The Home Induction trial: A randomised open-label trial to assess outpatient induction of labour, and compare efficacy of Propess vs Dilapan-S® for induction of labour at 39 weeks’ gestation in nor...
    Medical condition: Normal risk nulliparous women who have no pregnancy-related or medical contraindication to Induction of Labour
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004865 10055563 Labor induction LLT
    Population Age: Adults Gender: Female
    Trial protocol: IE (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 12 07:59:34 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA